GHG vs MED

GHG presents a classic 'value trap' profile, characterized by a strong Piotroski F-Score of 7/9 and extreme undervaluation relative to its Graham Number ($3.80) and Intrinsic Value ($1.82). While the company maintains healthy liquidity (Current Ratio 1.64) and positive margins, it is plagued by negative revenue growth (-15% YoY) and a catastrophic 5-year price decline of 88.8%. The deterministic health scores suggest operational stability, but the market is pricing in a structural decline in the business model, as evidenced by the 0/100 technical trend.

Medifast exhibits severe operational distress, highlighted by a weak Piotroski F-Score of 2/9 and a catastrophic YoY EPS decline of 1750%. While the company maintains a fortress balance sheet with very low debt (Debt/Equity 0.05) and high liquidity (Current Ratio 4.69), these strengths are overshadowed by a collapsing top line (-36.9% revenue growth). The stock is trading at a deep discount to book value (P/B 0.57), but the fundamental trajectory suggests a 'value trap' rather than a recovery opportunity.